Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why PharMerica Corporation (PMC) Shares Sank

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of PharMerica Corporation (NYSE:PMC), the second-largest nursing home pharmacy in the U.S., dipped as much as 19% after the company disclosed the loss of a large client in an 8-K filed with the Securities and Exchange Commission after the bell yesterday.

So what: According to its SEC filing, PharMerica Corporation (NYSE:PMC) has been informed by Kindred Healthcare, Inc. (NYSE:KND), its largest customer, that it would not be renewing its contract for skilled nursing pharmacy services when it’s due to expire on Dec. 31. Kindred Healthcare, Inc. (NYSE:KND) was responsible for 11.5% of PharMerica Corporation (NYSE:PMC)’s total revenue last year. To add insult to injury, Bank of America Corp (NYSE:BAC)/Merrill Lynch cut its price target on PharMerica Corporation (NYSE:PMC) by $1 to $17 from $18, citing the projected loss of 10% of gross profit, although it did also point to cost savings from no longer dealing with Kindred as a positive.

Now what: No magic wand is going to fix the loss of PharMerica Corporation (NYSE:PMC)’s largest customer — at least in the short run. On paper, PharMerica Corporation (NYSE:PMC)’s story makes sense because an aging baby boomer population will soon need greater access to medical care of all forms, including within nursing facilities. However, I have to wonder if Kindred’s departure is an anomaly or a trend of things to come in a highly competitive space. For now I’d suggest sticking to the sidelines and seeing how the next few quarters play out for PharMerica.

Craving more input? Start by adding PharMerica to your free and personalized watchlist so you can keep up on the latest news with the company.

While you can certainly make huge gains in pharmacy stocks like PharMerica, the best investing approach is to choose great companies and stick with them for the long term.

The article Why PharMerica Shares Sank originally appeared on

Fool contributor Sean Williams owns shares of Bank of America, but has no material interest in any other companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. The Motley Fool owns shares of, and recommends, Bank of America.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!